Afatinib dimaleate

Synonyms: 双马来酸盐阿法替尼; BIBW 2992MA2
Afatinib (BIBW 2992) dimaleate 是一种口服有效且不可逆的 ErbB 家族 (EGFR 和 HER2) 双特异性抑制剂,对 EGFRwt、EGFRL858R、EGFRL858R/T790M 和 HER2 的 IC50 值分别为 0.5 nM、0.4 nM、10 nM 和 14 nM,可用于食管鳞状细胞癌 (ESCC)、非小细胞肺癌 (NSCLC) 和胃癌的研究。
产品编号: MS-Z57188 纯度: 99.74% CAS No.: 850140-73-7 分子式: C32H33ClFN5O11 分子量: 718.08
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

Afatinib (BIBW 2992) dimaleate 是一种口服有效且不可逆的 ErbB 家族 (EGFR 和 HER2) 双特异性抑制剂,对 EGFRwt、EGFRL858R、EGFRL858R/T790M 和 HER2 的 IC50 值分别为 0.5 nM、0.4 nM、10 nM 和 14 nM,可用于食管鳞状细胞癌 (ESCC)、非小细胞肺癌 (NSCLC) 和胃癌的研究。

生物实验数据

生物活性 Afatinib (BIBW 2992) dimaleate is an orally active and irreversible dual-specificity inhibitor of the ErbB family (EGFR and HER2) with IC50 values of 0.5 nM, 0.4 nM, 10 nM, and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M, and HER2, respectively, and can be used for research on esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), and gastric cancer.
IC50 & Target HER2:14 nM, EGFR (L858R):0.4 nM, EGFR (WT):0.5 nM, EGFR (L858R/T790M):10 nM
体外研究
(In Vitro)

Afatinib dimaleate (100 nM) 充分防止调蛋白刺激的 HER3 磷酸化。
Afatinib dimaleate (0-10000 nM) 有效抑制异位表达 EGFR 的 NIH-3T3 细胞的贴壁非依赖性增殖突变体,并抑制 H1666、H3255 和 NCI 1975 细胞的细胞增殖。
Afatinib dimaleate (48-72 h) 在 HKESC-1、HKESC-2、SLMT-1 和 EC-1 细胞。
Afatinib dimaleate (0-1 μM,24-48 h) 抑制 AKT 和 MAPK 通路,并抑制 ESCC 中的 EGFR 和 AKT 磷酸化cell lines。
Afatinib dimaleate (0-1 μM,16-48 h) 在 HKESC-2 和 EC-1 中诱导 G0/G1 细胞周期停滞。
Afatinib dimaleate (0-1 μM,24-48 h) 有效诱导 HKESC-2 和 EC-1 细胞凋亡。

Cell Proliferation Assay

Cell Line: NIH-3T3 cells, H1666, H3255, and NCI 1975 cells
Concentration: 0, 1, 10, 100, 1000, 10000 nM
Incubation Time:
Result: Effectively inhibited anchorage-independent proliferation of NIH-3T3 cells ectopically expressing EGFR mutants. Showed inhibition of anchorage independent cell proliferation of various lung cancer cell lines (H1666, H3255, and NCI 1975 cells), with IC50 values of 60 nM, 0.7 nM and 99 nM, respectively.

Cell Viability Assay

Cell Line: HKESC-1, HKESC-2, SLMT-1 and EC-1 cell lines
Concentration:
Incubation Time: 48 and 72 hours
Result: Observed over 95% of growth inhibition. The respective IC50 concentrations at 48 hours (HKESC-1=0.078 μM, HKESC-2=0.115 μM, KYSE510=3.182 μM, SLMT-1=4.625 μM and EC-1=1.489 μM) and 72 hours (HKESC-1=0.002 μM, HKESC-2=0.002 μM, KYSE510=1.090 μM, SLMT-1=1.161 μM and EC-1=0.109 μM) were all in lower micro-molar range.

Western Blot Analysis

Cell Line: HKESC-2 cells and EC-1 cells
Concentration: 0, 0.01, and 0.1 μM (HKESC-2 cells), 0, 0.1 and 1 μM (EC-1 cells)
Incubation Time: 24 and 48 hours
Result: Reduced the phosphorylation of EGFR and the endogenous expression level of HER2 receptors in ESCC cells. Suppressed AKT phosphorylation in a dose and time dependent manner. Significantly reduced the phosphorylation level of the downstream effectors of the AKT-mTOR axis especially in HKESC-2 cells. Inhibited the two major downstream pathways of the ErbB/HER axis, namely, AKT and MAPK pathways in ESCC cell lines.

Cell Cycle Analysis

Cell Line: HKESC-2 cells and EC-1 cells
Concentration: 0, 0.01, and 0.1 μM (HKESC-2 cells), 0, 0.1 and 1 μM (EC-1 cells)
Incubation Time: 16, 24, and 48 hours
Result: Induced G0/G1 cell cycle arrest in both tested ESCC cell lines in a time and dose dependent manner. In HKESC-2 cells, the percentage of cells in G0/G1 phase was increased from 38.2% to 68.1% at 0.01 μM of afatinib and to 74.7% at 0.1 μM of afatinib, from 24 hours (82.4% G0/G1 arrest at 0.01 μM and 86.2% at 0.1 μM) to 48 hours (from 74.7% to 88.2% for 0.01 μM and 91.0% for 0.1 μM). In EC-1 cells, the percentage of cells arrested in the G0/G1 phase was increased from 59.1% to 66.6% and 72.2% at 24 and 48 hours respectively.

Apoptosis Analysis

Cell Line: HKESC-2 cells and EC-1 cells
Concentration: 0, 0.01, and 0.1 μM (HKESC-2 cells), 0, 0.1 and 1 μM (EC-1 cells)
Incubation Time: 24 and 48 hours
Result: Effectively induced cell death by triggering apoptotic mechanisms in ESCC cell lines. Showed a stronger expression level of cleaved Poly (ADP-ribose) polymerase (PARP) in these cell lines.
体内研究
(In Vivo)

Afatinib dimaleate (0 -20 mg/kg,口服,每日一次,持续 25 天) 显示显著的肿瘤消退和 EGFR、HER2、HER3 和 AKT 磷酸化下调。
Afatinib dimaleate (15 mg/kg,口服,5 天加停 2 天,持续两周) 强烈抑制 HKESC-2 肿瘤的生长。

Animal Model: Athymic NMRI-nu/nu female mice (21–31 g, five to six-week-old, transgenic murine lung cancer model and xenograft models)
Dosage: 15 mg/kg, 20 mg/kg
Administration: Orally, daily for 25 days
Result: Resulted in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2% in a standard xenograft model of the epidermoid carcinoma cell line A431, and downregulation of EGFR and AKT phosphorylation. Induced regression of large tumors in this HER2-driven model, effectively controlled xenograft tumor formation by the NCIH1975 cell line, expressing EGFR L858R/T790M, with a T/C value of 12% for doses of 20 mg/kg. Induced more than 50% percent tumor reduction after a 4-week treatment period. Downregulated EGFR, HER2 and HER3 phosphorylation.
Animal Model: Six weeks old female athymic nude mice (nu/nu) (16-20 g)
Dosage: 15 mg/kg
Administration: Oral gavage in a schedule of 5 days on plus 2 days off, for two weeks
Result: Strongly inhibited the growth of HKESC-2 tumor. Average tumor sizes of vehicle and treatment at end point are 348 ± 24 mm3 and 108 ± 36 mm3 respectively.
性状 固体
颜色 White to yellow

化学信息

分子量 718.08
分子式 C32H33ClFN5O11
CAS No. 850140-73-7
别名 双马来酸盐阿法替尼; BIBW 2992MA2

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (139.26 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 50 mg/mL (69.63 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM1.3926 mL6.9630 mL13.9260 mL34.8151 mL
5 mM0.2785 mL1.3926 mL2.7852 mL6.9630 mL
10 mM0.1393 mL0.6963 mL1.3926 mL3.4815 mL
15 mM0.0928 mL0.4642 mL0.9284 mL2.3210 mL
20 mM0.0696 mL0.3482 mL0.6963 mL1.7408 mL
25 mM0.0557 mL0.2785 mL0.5570 mL1.3926 mL
30 mM0.0464 mL0.2321 mL0.4642 mL1.1605 mL
40 mM0.0348 mL0.1741 mL0.3482 mL0.8704 mL
50 mM0.0279 mL0.1393 mL0.2785 mL0.6963 mL
60 mM0.0232 mL0.1161 mL0.2321 mL0.5803 mL
DMSO80 mM0.0174 mL0.0870 mL0.1741 mL0.4352 mL
100 mM0.0139 mL0.0696 mL0.1393 mL0.3482 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础